1Lee LY,Patel SR,Hackett NR,et al. Focal angingen therapy using intramyocardial delivery of an adanovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg, 2000,69(1) : 14-23.
2Sayeed SU, Mann MJ, Martin J,et al. Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with tansmyocardial laser revascularization. J Thorac Cardiovasc Surg,1998,116:763-769.
3Rosengart TK, Lee LY,Patel SR,et al. Angingenesis gene therapy:phase I assessment of direct intramyocardial administration of anadenovirus vector expressing VEGFI21 cDNA to individuals with clinically significant severe coronary artery disease. Circulation,1999,100(5) :468-474.
4Huwer H,Welter C, Qzbek C, et al. Simultaneous surgical revascularization and angiogenesis gene therapy in diffuse coronary artery disease. Eur J Cardiothora Surg.2001.20(6) : 1128- 1134.
5Sarkar N,Ruok A, Kallner G,et al. Effects of intromyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease-12-month follow-up: angiogenie gene therapy. J Intern Med, 2001,250(5) :373-378.
6Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 Placebo-controlled, double-blind,dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation, 2002, 105(17):2012-2018.
7Zimmerman MA, Selzman LH, Raeburn CD, et al. Clinical app|ications of cardiovascular angiogenesis. J Card Surg, 2002,1696) : 290-497
8Jingjing L, Srinivasan B, Bian X, et al. Vascular endothelial growth factor is increased following corcnary artery occlusion in the dog heart. Mol Cell Bioehexn, 2000,214(1 - 2) :23-30.
9Henry TD, Roeha Sk, lsner JM, et al. lntracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J, 2001,142(5):872-880.
10harvey BG,Maroni J,O'Donoghue KA, et al. Safety of local dilivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrtma of comorbid conditions. Hum Gene Ther,2002,13(1) : 15-63.
3Yamagishi S,Youekura H,Yamamoto Y,et al.Vascular endothelial growth factor acts as apericyte nitrogen under hypoxic condition[J].Lab Invest,1999,79(4):501-509.
4Pourati I,Kimmelstiel C,Rand W,et al.Statin use is associate with enhanced collateralization of severely diseased coronararteries[J].Am Heart J,2004,148:21-23.
5郑筱芋.中药新药临床研究指导原则[M].中国医药出版社,2002.67-71.
6Michel W,Christopher H,Alec JG,et al.Statins have biphasic effects on angiogenesis[J].Circulation,2002,105:739-745.
7Babaei S,Stemart DJ.Over expression of endothelial NO synthas induces angiogenesis in acoculture mode l[J].Cardiovasc Res,2002,55:190-200.
8Kimura H.Hypoxiaresponse element of the human vascular endothelial growth factor gene mediate stran scriptional regulation nitric oxide:control of hypoxia-induc -ible-factor-1 activity by nitri oxide[J].Blood,2000,95:189-197.
9Cai WJ,Kocsis E,Luo X,et al.Expression of endothelial nitric oxide synthase in the vascular wall during arteriogenesis[J].Mol Cell Biochem,2004,264(1-2):193-200.
10Yamagishis G,Youekura H,Yamamotoy M,et al.Vascular endothelial growth factor acts as apericyte nitrogen under hypoxic condition[J].J Lab Invest (S0023-6837),1999,79(4):501-509.
